New antiepileptic drugs and neuropathic pain. from molecular medicine to clinical practice;Nuevos fármacos antiepilépticos y dolor neuropático. De la medicina molecular a la clínica

Medicina Clinica

Volumn 129, Issue 14, 2007, Pages 542-550

  Bermejo Velasco, Pedro Emilio ^a   Velasco Calvo, Rocío ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Gabapentin; Lamotrigine; Neuropathic pain; Pregabalin; Topiramate; Zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PREGABALIN; TOPIRAMATE; ZONISAMIDE;

ATAXIA; CLINICAL PRACTICE; CLOSED ANGLE GLAUCOMA; DECREASED APPETITE; DIPLOPIA; DRUG EFFICACY; DRUG MECHANISM; DYSARTHRIA; EDEMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPONATREMIA; NAUSEA; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NOCICEPTION; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRURITUS; PSYCHOSIS; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; URTICARIA;

EID: 36049016785     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13111432     Document Type: Review

References (172)

1. Carneado-Ruiz J, Morera-Guitart J, Alfaro-Sáez A, Turpin-Fenoll L, Serna-Candel C, Matías-Guiu Guía J. El dolor neuropático como motivo de consulta en neurología: análisis de su frecuencia. Rev Neurol. 2005; 41:643-8.
2. Pardo-Fernández J, Gutiérrez-Rivas E, Montero-Homs J, Navarro C. Tratamiento del dolor neuropático en las consultas de neurología. Estudio PREVADOL. Rev Neurol. 2006;42:451-4.
3. Thomas RJ. Excitatory amino acids in health and disease. J Am Geriatr Soc. 1995;43:1279-89.
4. Coderre TJ, Melzack R. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J Neurosci. 1992;12:3665-70.
5. Field MJ, McCleary S, Hughes J, Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain. 1999;80:391-8.
6. Sotah M, Foong FW. A mechanism of carbamazipine analgesia as shown by bradykinin-induced trigeminal pain. Brain Res Bull. 1983; 10:407-9.
7. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837-42.
8. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831-6.
9. Caviedes BE, Herranz JL. Avances en la fisiopatología y en el tratamiento del dolor neuropático. Rev Neurol. 2002;35:1037-48.
10. Rome HP, Rome JD. Limbically augmented pain syndrome - LAPS. Pain. 2000;1:9-21.
11. Chung JM, Chung K. Importance of hyperexcitability of DRG neurons in neuropathic pain. Pain Pract. 2002;2:87-97.
12. Mamet J, Baron A, Lazdunski M, Voilley N. Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acidsensing ion channels. J Neurosci. 2002;22:10662-70.
13. Decker MW, Meyer MD, Sullivan JP. The therapeutic potential of nicotinic acetylcholine receptor antagonists for pain control. Expert Opin Investig Drugs. 2001;10:1819-30.
14. Cunha JM, Cunha FQ, Poole S, Ferreira SH. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br J Pharmacol. 2000;130:1418-24.
15. Waxman SG. Adquired channelopathies in nerve injury and MS. Neurology. 2001;56:1621-7.
16. Gurtu S, Smith PA. Electrophysiological characteristics of hamster dorsal root ganglion cells and their response to axotomy. J Neurophysiol. 1988;79:2668-78.
17. Bolay H, Moskowitz MA. Mechanisms of pain modulation in chronic syndromes. Neurology. 2002;59 Suppl 2:2-7.
18. Mannion JR, Woolf CJ. Pain mechanisms and management: a central perspective. Clin J Pain. 2000;16 Suppl 3:144-56.
19. Zhang X, Wu J, Lei Y, Fang L, Willis WD. Protein phosphatase 2A regulates central sensitization in the spinal cord of rats following intradermal injection of capsaicin. Mol Pain. 2006;20:2-9.
20. Woolf CJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature. 1992;355:75-8.
21. Xie YF, Zhang S, Chiang CY, Hu JW, Dostrovsky JO, Sessle BJ. Involvement of glia in central sensitization in trigeminal subnucleus caudalis (medullary dorsal horn). Brain Behav Immun. 2007;21:634-41.
22. Zhang S, Chiang CY, Xie YF, Park SJ, Lu Y, Hu JW, et al. Central sensitization in thalamic nociceptive neurons induced by mustard oil application to rat molar tooth pulp. Neuroscience. 2006;142:833-42.
23. Gwak YS, Tan HY, Nam TS, Paik KS, Hulsebosch CE, Leem JW. Activation of spinal GABA receptors attenuates chronic central neuropathic pain after spinal cord injury. J Neurotrauma. 2006;23:1111-24.
24. Abraham KE, McGinty JF, Brewer KL. The role of kainic acid/AMPA and metabotropic glutamate receptors in the regulation of opioid mRNA expression and the onset of pain-related behavior following excitotoxic spinal cord injury. Neuroscience. 2001;104:863-74.
25. Lidbeck J. Central hyperexcitability in chronic musculoskeletal pain: a conceptual breakthrough with multiple clinical implications. Pain Res Manag. 2002;7:81-92.
26. Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain. 2000;4:5-15.
27. Devor M. Sodium channels and mechanisms of neuropathic pain. J Pain. 2006;7 Suppl 1:3-12.
28. Ekberg J, Adams DJ. Neuronal voltage-gated sodium channel subtypes: key roles in inflammatory and neuropathic pain. Int J Biochem Cell Biol. 2006;38:2005-10.
29. Hains BC, Saab CY, Waxman SG. Alterations of burst firing of thalamic VPL neurons and reversal by Na(v)1.3 antisense after spinal cord injury. J Neurophysiol. 2006;95:3343-52.
30. Lindia JA, Kohler MG, Martin WJ, Abbadie C. Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats. Pain. 2005;117:145-53.
31. Okuse K, Malik-Hall M, Baker MD, Poon WY, Kong H, Chao MV, et al. Annexin II light chain regulates sensory neuron specific sodium channel expression. Nature. 2002;47:653-6.
32. Zhou X, Dong XW, Crona J, Maguire M, Priestey T. Vinpocetine is a potent blocker of rat NaV1.8 tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther. 2003;306:498-504.
33. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha-2-delta subunit of a calcium channel. J Biol Chem. 1996; 271:5768-76.
34. Gong HC, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI, et al. Tissue-specific expression and gabapentin binding properties of calcium channel alpha-2-delta subunit subtypes. J Membr Biol. 2001; 184:35-43.
35. Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CY, et al. Injury type-specific calcium channel alpha-2-delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther. 2002;303:1199-205.
36. Li CY, Zhang XL, Matthews EA, Li KW, Kurwa A, Boroujerdi A, et al. Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. Pain. 2006;125:20-34.
37. 2+ channel. EMBO J. 2001;20:2349-56.
38. Klotz U. Ziconotide - a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain - a short review. Int J Clin Pharmacol Ther. 2006;44:478-83.
39. Rasband NM, Park EW, Wanderah TW, Lai J, Porreca F, Trimmer JS. Distinct potassium channels on pain-sensing neurons. Proc Natl Acad Sci USA. 2001;98:13373-8.
40. Passmore GM, Selyanko AA, Mistry M, Al-Qatari M, Marsh SJ, Matthews EA, et al. KCNQ/M currents in sensory neurons: significance for pain therapy. J Neurosci. 2003;23:7227-36.
41. Hu HJ, Carrasquillo Y, Karim F, Jung WE, Nerbonne JM, Schwarz TL, et al. The kv4.2 potassium channel subunit is required for pain plasticity. Neuron. 2006;50:89-100.
42. Madeja M, Margineanu DG, Gorji A, Siep E, Boerrigter P, Klitgaard H, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology. 2003;45:661-71.
43. Cooper EC, Jan LY. M-channels: neurological diseases, neuromodulation, and drug development. Arch Neurol. 2003;60:496-500.
44. Avedaño C, Machín R, Bermejo PE, Lagares A. Neuron numbers in the sensory trigeminal nuclei of the rat: a GABA- and glycine- immunocytochemical and stereological analysis. J Comp Neurol. 2005;493:538-53.
45. Pedersen LH, Scheel-Kruger J, Blackburn-Munro G. Amygdala GABAA receptor involvement in mediating sensory-discriminative and affective-motivational pain responses in a rat model of peripheral nerve injury. Pain. 2007;127:17-26.
46. Chaplan SR, Luo HQ, Lee DH, Luo L, Lui C, Kueri C, et al. Neuronal hyperpolarization-activated pacemaker channels drive neuropathic pain. J Neurosci. 2003;23:1169-78.
47. Luo L, Chang L, Brown SM, Ao H, Lee DH, Higuera ES, et al. Role of peripheral hyperpolarization-activated cyclic nucleotide-modulated channel pacemaker channels in acute and chronic pain models in the rat. Neuroscience. 2007;144:1477-85.
48. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001;429:71-8.
49. Boyce S, Wyatt A, Webb JK, O'Donnell R, Mason G, Rigby M, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localization of NR2B subunit in dorsal horn. Neuropharmacology. 1999;38:611-23.
50. Brown DG, Krupp JJ. N-methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics. Curr Top Med Chem. 2006;6:749-70.
51. Simmons RM, Webster AA, Kalra AB, Iyengar S. Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats. Pharmacol Biochem Behav. 2002;73:419-27.
52. Torsney C, Macdermott AB. AMPA receptors bring on the pain. Neuron. 2004;44:577-8.
53. Hartmann B, Ahmadi S, Heppenstall PA, Lewin GR, Schott C, Borchardt T, et al. The AMPA receptor subunits GluR-A and GluR-B reciprocally modulate spinal synaptic plasticity and inflammatory pain. Neuron. 2004;44:637-50.
54. Lee HJ, Pogatzki-Zahn EM, Brennan TJ. The effect of the AMPA/kainate receptor antagonist LY293558 in a rat model of postoperative pain. J Pain. 2006;7:768-77.
55. North RA. The P2X3 subunit: a molecular target in pain therapeutics. Curr Opin Invest Drugs. 2003;4:833-40.
56. Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, et al. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature. 2003;424:778-83.
57. Jarvis MF, Burgard EC, McGaraughty S, Honore P, Lynch K, Brennan TJ, et al. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci. 2002;99:17179-84.
58. Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP, et al. A-740003 [N- (1-{[cyanoimino) (5-quinolynilamino) methyl] amino} -2,2- dimethylpropyl) -2- (3,4 - dimethoxiphenyl) acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther. 2006;319:1376-85.
59. Nasu-Tada K, Koizumi S, Tsuda M, Kunifusa E, Inoue K. Possible involvement of increase in spinal fibronectin following peripheral nerve injury in upregulation of microglial P2X4, a key molecule for mechanical allodynia. Glia. 2006;53:769-75.
60. Fukuoka T, Tokunaga A, Tachibana T, Dai Y, Yamanaka H, Noguchi K. VR1, but not P2X(3), increases in the spared L4 DRG in rats with L5 spinal nerve ligation. Pain. 2002;99:111-20.
61. Hudson LJ, Bevan S, Wotherspoon G, Gentry C, Fox A, Winter J. VR1 protein expression increases in undamaged DRG neurons after partial nerve injury. Eur J Neurosci. 2001;13:2105-14.
62. Rashid MH, Inoue M, Kondo S, Kawashima T, Bakoshi S, Ueda H. Novel expression of vanilloid receptor 1 on capsaicin-insensitive fibers accounts for the analgesic effect of capsaicin cream in neuropathic pain. J Pharmacol Exp Ther 2003;304:940-8.
63. Christoph T, Grunweller A, Mika J, Schafer MK, Wade EJ, Weihe E, et al. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem Biophys Res Commun. 2006;350: 238-43.
64. Fox A, Bevan S. Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin Investig Drugs. 2005;14:695-703.
65. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348:1223-32.
66. Schafers M, Sorkin LS, Geis C, Shubayev VI. Spinal nerve ligatino induces transient upregulation of tumor necrosis factor receptors 1 and 2 in injured and adjacent uninjured dorsal root ganglia in the rat. Neurosci Lett. 2003;347:179-82.
67. Okamoto K, Martin DP, Schmelzer JD, Mitsui Y, Low PA. Pro- and antiinflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp Neurol. 2001;169: 386-91.
68. Sommer C, Schmidt C, George A, Toyka KV. A metalloprotease-inhibitor reduces pain associated behavior in mice with expresimental neuropathy. Neurosci Lett. 1997;237:45-8.
69. Sommer C, Martiniak M, Myers RR. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain. 1998;74:83-91.
70. Holmes FE, Bacon A, Pope RJ, Vanderplank PA, Kerr NC, Sukumaran M, et al. Transgenic overexpression of galanin in the dorsal root ganglia modulates pain-related behavior. Proc Natl Acad Sci U S A. 2003;100:6180-5.
71. Mabuchi T, Matsumura S, Okura-Ashikata E, Kitano T, Kojima H, Nagano T, et al. Attenuation of neuropathic pain by the nociceptin/orphalin FQ antagonist JTC-801 is mediated by inhibition of nitric oxide production. Eur J Neurosci. 2003;17:1384-92.
72. Takahashi N, Nagano M, Suzuki H, Umino M. Expression changes of glial cell line-derived neurotrophic factor in a rat model of neuropathic pain. J Med Dent Sci. 2003;50:87-92.
73. Blom S. Trigeminal neuralgia: its treatment with a new antieconvulsant drug. Lancet. 1962;1:839-40.
74. Campbell FG, Graham JG, Zillkha KJ. Clinical trial of carbamazepine (Tegretol) in trigeminal neuralgia. J Neurosurg Neurol Psychiatry. 1966;29:265-7.
75. Gerson GR. Studies on the concomitant use of carbamazepine and clomipramine for the relief of post-herpetic neuralgia. Postgrad Med J. 1977;53 Suppl 4:104-9.
76. Leijon G, Boivie J. Central post-stroke pain - a controlled trial of amitriptyline and carbamazepine. Pain. 1987;28:45-50.
77. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain. 1997;73:123-79.
78. Galer BS. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology. 1995;45 Suppl 9:17-25.
79. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsivant drugs for management of pain: a systematic review. BMJ. 1995;311: 1047-52.
80. Sorensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand. 1988;78:346-8.
81. Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, et al. Topiramate in essential tremor. Neurology. 2006;66:672-7.
82. Rickels K, Pollack MH, Feltner DE, Lydiard B, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: A 4-week, multicenter, double-blind, placebo-controlled trial of pregabalina and alprazolam. Arch Gen Psychiatry. 2005;62:1022-30.
83. Asconape JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol. 2002;22:27-39.
84. Martínez-Salio A, Porta-Etessam J, Berbel-García A, García-Morales I, De la Peña-Mayor P, Vicente-Fatela L. Fármacos antiepilépticos y dolor neuropático. Rev Neurol. 2001:32:345-50.
85. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology. 2002;59 Suppl 2:14-7.
86. Bazil CW. Anticonvulsant drug or neuromodulator? The growing case for anticonvulsant uses beyond epilepsy. Curr Neurol Neurosci Rep. 2004;4:305-7.
87. Mao J, Chen LL. Gabapentin in pain management. Anesth Analg. 2000;91:680-7.
88. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29:233-49.
89. Lynch JJ, Honore P, Anderson DJ, Bunnelle WH, Mortell KH, Zhong C, et al. (L)-phenylglycine, but not necessarily other alpha2delta subunit voltage-gated calcium channel ligands, attenuates neuropathic pain in rats. Pain. 2006;125:136-42.
90. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs amitriptyline in painful diabetic neuropathy: An open-label pilot study. J Pain Symptom Manage. 2000;20:280-5.
91. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the treatment of painful neuropathy in patients with diabetes mellitus: a randomised controlled trial. JAMA. 1998;280: 1831-6.
92. Backonja MM. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia. 1999;40 Suppl 6:57-9.
93. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpética neuralgia: a randomised controlled trial. JAMA. 1998;280:1837-42.
94. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999;159:1931-7.
95. Sist T, Filadora V, Miner M, Lema M. Gabapentin for idiopathic trigeminal neuralgia: report of two cases. Neurology. 1997;48:1467.
96. Guerrero-Figueroa R, Escobar-Juyo A, Caballero-García G, Blanco-Castillo IP. Efecto de la gabapentina en la alodinia bucofacial. Correlación experimental de neuralgia trigeminal. Rev Neurol. 1999;29:1147-53.
97. Cheshire WP Jr. Defining the role for gabapentin in the treatment of trigeminal neuralgia: a retrospective study. J Pain. 2002;3:137-42.
98. García-Callejo FJ, Velert-Vila MM, Talamanes-Escriba F, Blay-Galaud L. Respuesta clínica de la neuralgia del glosofaríngeo a la gabapentina. Rev Neurol. 1999;28:380-4.
99. Samkoff LM, Daras M, Tuchman AJ, Doppel BS. Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin. Neurology. 1997;49:304-5.
100. Houtchens MK, Richert JR, Sami A, Rose JW. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler. 1997;3:250-3.
101. Sist TC, Filadora VA, Miner M, Lema M. Experience with gabapentin for neuropathic pain in the head and neck: report of ten cases. Reg Anesth. 1997;22:473-8.
102. Khatri A, Pearlstein L. Pain in Guillain-Barré syndrome. Neurology. 1997;49:1474.
103. Caraceni A, Zecca E, Martini C, De-Conno F. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage. 1999;17:441-5.
104. Mellick GA, Mellick LB. Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Rehabil. 1997;78:98-105.
105. Ben-David B, Friedman M. Gabapentin therapy for vulvodynia. Anesth Analg. 1999;89:1459-60.
106. Lesser H, Sharma U, LaMoreux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomised controlled trial. Neurology. 2004;63:2104-10.
107. Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45:20-7.
108. Hill DR, Suman-Chauhan N, Woodruff GN, Localization of (3H) gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol. 1993;244:303-9.
109. Freyhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible and fixed-dose regimens. Pain. 2005;115:254-63.
110. Taylor CP, Vartanian MG, Yuen PW, Bigge C, Suman-Chauhan N, Hill DR. Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by triated gabapentin. Epilepsy Res. 1993;14:11-5.
111. López-Trigo J, Sancho Rieger J. Pregabalina. Un nuevo tratamiento para el dolor neuropático. Neurología. 2006;21:96-103.
112. Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreux L, Bockbrader H, et al. Pregabalin for the treatment of postherpética neuralgia: a randomised, placebo-controlled trial. Neurology. 2003;60:1274-83.
113. Strojek K, Balkenohl M, Griesing T. Pregabalin in the management of chronic neuropathic pain syndromes: evaluation of fixed and flexible dosing. Eur J Neurol. 2004;11 Suppl 2:131.
114. Van Seventer HF, Young JP, Versavel M. Pregabalin dosed twice daily improves health related quality of life in patients with postherpética neuralgia. Eur J Neurol. 2004;11 Suppl 2:132.
115. Sharma U, Allen R, Glessner C, Hes M, Lamoreaux L, Poole RM. Pregabalin effectively relieves pain in patients with diabetic peripheral neuropathy; Study 1008-014. Diabetes. 2000;49 Suppl 1:187.
116. Lacobelli D, Allen R, LaMoreaux L, Poole RM. A double blind placebo-controlled trial of pregabalin for the treatment of painful diabetic peripheral neuropathy. Neurology. 2000;54 Suppl 3:177.
117. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253-60.
118. Guille C, Sachs G. Clinical outcome of adjunctive topiramate in a sample of refractory bipolar patients with comorbid conditions. Prog Neuropsycopharm Biol Psychiatry. 2002;26:1035-9.
119. Dorado R, Gómez-Argüelles JM, Herrera A, Aragón E, Blanco M, Gilo-Arrojo F, et al. Topiramato en enfermedades comórbidas: epilepsia y migraña. Rev Neurol. 2006;43:193-6.
120. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised control trial. Lancet. 2003;361:1677-85.
121. McElroy SL, Arnold LM, Shapira NA, Keck PE Jr, Rosenthal NR, Karim MR, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160:255-61.
122. Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clin J Pain. 2003;19:59-68.
123. White HS, Brown D, Skeen GA, Twyman RE. The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride currents. Epilepsia. 1995;36 Suppl:39.
124. Nieto-Barrera M. Características e indicaciones de topiramato. Rev Neurol. 2002;35 Supl 1:88-95.
125. Kiline MK, Carroll GD, Malnar FK. Painful diabetic neuropathy relieved with use of oral topiramate. South Med J. 2003;96:602-5.
126. Bajwa ZH, Sami N, Warfield CA, Wootton J. Topiramate relieves refractory intercostals neuralgia. Neurology. 1999;52:1917.
127. Langtry HD, Gillis JC, Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs. 1997;54:752-73.
128. Schneiderman JH. Topiramate: pharmacokinetics and pharmacodynamics. Can J Neurol Sci. 1998;25:S3-S5.
129. Glauser TA. Topiramate. Epilepsia. 1999;40 Suppl 5:71-80.
130. Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther. 1997;19:1294-308.
131. Edwards KR, Glanz MJ, Button J. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Neurology. 2000;54:81.
132. Vinik A, Hewitt D, Xiang J. Topiramate in the treatment of painful diabetic neuropathy: results from a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology. 2003;60 Suppl 1:154-5.
133. Zvartau-Hind M, Din MU, Gilani A, Lisak RP, Khan OA. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology. 2000;55:1587-8.
134. Dib JG. Focus on topiramate in neuropathic pain. Curr Med Res Opin. 2004;20:1857-61.
135. Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther. 2003;25:2506-38.
136. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004;61:1-48.
137. Hasegawa H. Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. Curr Med Res Opin. 2004;20:577-80.
138. Takahashi Y, Hashimoto K, Tsuji S. Successful use of zonisamide for central poststroke pain. J Pain. 2004;5:192-4.
139. Patel U, Cheville A, Kim P. Zonisamide for neuropathic pain: success with a novel adjuvant analgesic. J Pain. 2002;3 Suppl 1:41.
140. Krusz JC. Zonisamide as a treatment for chronic pain. J Pain. 2003;4 Suppl 1:86.
141. Leach MJ, Marden CM, Millar AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug II. Neurochemical studies on the mechanism of action. Epilepsia. 1986;27:490-7.
142. Nackamura-Craig M, Follenfant RL. Effect of lamotrigine in the acute and chronic hyperalgesia induced by PGE2 and in the chronic hyperalgesia in rats with streptozocin-induced diabetes. Pain. 1995;63:33-7.
143. Christensen C, Michèle G, Guilbaud G, Kayser V. Effect of gabapentin and lamotrigine on mechanical allodynia-like behaviour in a rat model of trigeminal neuropathic pain. Pain. 2001;93:147-53.
144. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain. A randomized controlled trial. Neurology. 2001;56:184-90.
145. Canavero S, Bonicalzi V. Clinical note. Lamotrigine control of central pain. Pain. 1996;68:179-81.
146. Finnerup NB, Sindrup SH, Bach FW, Johannensen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain. 2002;96:375-83.
147. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mulens EL. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain. 1997;73:223-30.
148. Simpson DM, McArthur, JC, Olney R, Clifford D, So Y, Ross D, et al. Lamotrigine for HIV-associated painful sensory neuropathies:a placebo-controlled trial. Neurology. 2003;60:1508-14.
149. Eisenberger E, Lurie Y, Braker C, Daud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57:505-9.
150. Messenheirmer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf. 1998;18:281-96.
151. Ceylan S, Karakus A, Duru S, Baykal S, Koca O. Glossopharyngeal neuralgia: a study of six cases. Neurosurg Rev. 1997;20:196-200.
152. Tripathi M, Kaushik S. Carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Crit Care Med. 2000;28:655-8.
153. Leijon G, Boivie J. Central post-stroke pain- a controlled trial of amitriptyline and carbamazepine. Pain. 1989;36:27-36.
154. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia. 1999;40:2-10.
155. Herranz JL, Argumosa A. Características e indicaciones de la oxcarbacepina. Rev Neurol. 2002;35 Supl 1:101-9.
156. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002;27:121-30.
157. Royal M, Wienecke G, Movva W, Ward S, Bhakta B, Jensen M, et al. Open label trial of oxcarbazepina in neuropathic pain. Pain Med. 2001; 2:250-1.
158. Fenollosa-Vázquez P, Canós-Verdecho MA, Núñez-Cornejo C, Pallarés-Delgado J. Eficacia y tolerancia de la oxcarbacepina en dolor neuropático crónico: estudio de 40 casos. Rev Neurol. 2005;40:711-5.
159. Carrazana E, Mikoshiba I. Racionale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Sympton Manage. 2003;25 Suppl 5:31-5.
160. Loscher W, Schmidt D. New horizons in the development of antiepileptic drugs: innovative strategies. Epilepsy Res. 2006;69:183-272.
161. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006;69:273-94.
162. Ardid D, Lamberty Y, Allouri A, Coudore-Civiale MA, Klitgaard H, Eschalier A. Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats. Eur J Pharmacol. 2003;473:27-33.
163. Price MJ. Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain. 2004;20:33-6.
164. Enggaard TP, Klitgaard NA, Sindrup SH. Specific effect of levetiracetam in experimental human pain models. Eur J Pain. 2006;10:193-8.
165. Ramael S, Daoust A, Toublanc N, Lu ZS, Stockis A. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia. 2006;47:1128-35.
166. Armijo JA, Adín J, Sánchez MB. Mecanismo de acción de los antiepilépticos y nuevos antiepilépticos. Rev Neurol. 2006;43 Supl 1:17-41.
167. Errington AC, Coyne L, Stohr T, Selve N, Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology. 2006;50:1016-29.
168. Stohr T, Krause E, Selve N. Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain. Eur J Pain. 2006;10: 241-9.
169. Beyreuther B, Callizot N, Stohr T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol. 2006;539:64-70.
170. Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol. 2003;460:109-16.
171. Hovinga CA. Valrocemide. Curr Opin Investig Drugs. 2004;5:101-6.
172. Winkler I, Blotnik S, Shimshoni J, Yagen B, Devor M, Bialer M. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br J Pharmacol. 2005;146:198-208.